3 Biotech Stocks That Could Make You Filthy Rich
These three low-priced cancer stocks could be grossly undervalued.
Why Acceleron Pharma Stock Jumped This Week
Buyout rumors are swirling around this mid-cap biotech company.
2 Best Biotech Stocks to Buy Right Now
Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.
Why Corvus Pharmaceuticals Stock Is Down Today
Profit taking appears to be in full effect today with this small-cap biotech.
Why Verastem Stock Spiked Today
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.
Why RedHill Biopharma Stock Is Getting Crushed Today
A clinical failure is sending shareholders to the exits this morning.
Why Dynavax Technologies Stock Is Sinking Today
A lost supply agreement for a partner's COVID-19 vaccine is hurting the biotech's shares today.
Why Biogen Stock Is Slipping Today
Aduhelm's commercial launch isn't off to a strong start.
Why eFFECTOR Therapeutics Stock Is Heating Up Today
The biotech's novel cancer platform is fueling buyout speculation on social media today.
Why Axsome Therapeutics Stock Cratered in August
An unexpected regulatory setback weighed heavily on the biotech's shares last month.
Why Curis Stock Perked Up in August
The biotech's shares rode the wave of buyout speculation higher last month.
Why Kadmon Holdings Stock Is Rocketing Higher Today
Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.
Why Adaptimmune Therapeutics Stock Is Spiking Today
The hunt for the next biotech buyout play is apparently underway.
Why Trillium Therapeutics Stock Is Skyrocketing Today
Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.
Why Axsome Therapeutics Stock Is Crashing Today
An unexpected regulatory setback is weighing on the biotech's shares today.
Why Ardelyx Stock Is Getting Crushed Today
The FDA doesn't appear to be impressed by the biotech's experimental kidney disease drug.
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
The biotech can't seem to catch a break.
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021
The biotech's shares have definitely lost their shine in 2021.
Why Amarin Stock Is Sinking Today
The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.